Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022
Marinus Pharmaceuticals (MRNS) announced plans to release its Q1 financial results on May 12, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
- Domestic: (888) 550-5280
- International: (646) 960-0813
- Webcast Link: https://events.q4inc.com/attendee/993378901
- Conference ID: 2696394
About
Marinus is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a neuroactive steroid GABAA receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. For more information visit www.marinuspharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005372/en/
Vice President, Corporate Affairs & Investor Relations
484-253-6792
sdamouni@marinuspharma.com
Source: